Tian Junbo, Zhang Jing, Yang Zengguang, Feng Shuaisheng, Li Shujuan, Ren Shiqi, Shi Jianxiang, Hou Xinyue, Xue Xia, Yang Bei, Xu Hongen, Guo Jiancheng
BGI College and Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Precision Medicine Center, Academy of Medical Science, Zhengzhou University, Zhengzhou, China.
Front Pharmacol. 2022 Feb 23;12:790832. doi: 10.3389/fphar.2021.790832. eCollection 2021.
Medication safety and efficacy-related pharmacogenomic research play a critical role in precision medicine. This study comprehensively analyzed the pharmacogenomic profiles of the central Han Chinese population in the context of medication safety and efficacy and compared them with other global populations. The ultimate goal is to improve medical treatment guidelines. We performed whole-genome sequencing in 487 Han Chinese individuals and investigated the allele frequencies of pharmacogenetic variants in 1,731 drug response-related genes. We identified 2,139 (81.18%) previously reported variants in our population with annotations in the PharmGKB database. The allele frequencies of these 2,139 clinical-related variants were similar to those in other East Asian populations but different from those in other global populations. We predicted the functional effects of nonsynonymous variants in the 1,731 pharmacogenes and identified 1,281 novel and 4,442 previously reported deleterious variants. Of the 1,281 novel deleterious variants, five are common variants with an allele frequency >5%, and the rest are rare variants with an allele frequency <5%. Of the 4,442 known deleterious variants, the allele frequencies were found to differ from those in other populations, of which 146 are common variants. In addition, we found many variants in non-coding regions, the functions of which require further investigation. This study compiled a large amount of data on pharmacogenomic variants in the central Han Chinese population. At the same time, it provides insight into the role of pharmacogenomic variants in clinical medication safety and efficacy.
药物安全性和疗效相关的药物基因组学研究在精准医学中发挥着关键作用。本研究在药物安全性和疗效背景下全面分析了中国中部汉族人群的药物基因组概况,并将其与其他全球人群进行比较。最终目标是改进医疗治疗指南。我们对487名汉族个体进行了全基因组测序,并研究了1731个与药物反应相关基因的药物遗传变异的等位基因频率。我们在我们的人群中鉴定出2139个(81.18%)先前在PharmGKB数据库中有注释报道的变异。这2139个临床相关变异的等位基因频率与其他东亚人群相似,但与其他全球人群不同。我们预测了1731个药物基因中非同义变异的功能效应,鉴定出1281个新的和4442个先前报道的有害变异。在1281个新的有害变异中,5个是等位基因频率>5%的常见变异,其余是等位基因频率<5%的罕见变异。在4442个已知有害变异中,发现其等位基因频率与其他人群不同,其中146个是常见变异。此外,我们在非编码区发现了许多变异,其功能需要进一步研究。本研究汇编了大量关于中国中部汉族人群药物基因组变异的数据。同时,它为药物基因组变异在临床药物安全性和疗效中的作用提供了见解。